Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brii Biosciences Limited ( (HK:2137) ) has shared an update.
Brii Biosciences Limited has announced promising 24-week post-treatment follow-up results from Cohort 4 of its Phase 2 ENSURE study, presented at the AASLD 2025. The study evaluates a novel treatment strategy for HBV using the company’s therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFN α. The results indicate a sustained hepatitis B surface antigen (HBsAg) loss in patients who responded to BRII-179, suggesting its potential to improve functional cure outcomes. This development could enhance the company’s position in the HBV treatment market and offer new hope for diverse patient populations.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases. The company is particularly active in the Asia-Pacific region and is engaged in creating treatments for hepatitis B virus (HBV) among other conditions.
YTD Price Performance: 84.69%
Average Trading Volume: 6,662,190
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.33B
For detailed information about 2137 stock, go to TipRanks’ Stock Analysis page.